Market pulse › Novo Nordisk

Novo Nordisk

Company tag · tracked since 24 Sept

Today0 stories · 0 articles6 stories since 24 Sept

Net tone–±0% over the week

Market checkNo price to compare for this tag

Developing0 storylinesNone active in the last 14 days

Stories per day

Bar colour is the day’s tone · tracking began on 24 Sept

224 Sept

425 Sept

026 Sept

027 Sept

028 Sept

stories together this week · colour is their tone

6 in all · newest first

Expansion● mixedNovo is betting on its next chapter as Eli Lilly gains more ground in GLP-1sAnalysts say Lilly may have advantages as Novo tries to regain ground in the obesity drug marketEli Lilly Pharma and healthcare1 source
3d

Deal● mixedNanexa shares surge on €1.17 billion Novo Nordisk licensing dealNanexa shares more than doubled after announcing the drug-delivery licensing dealPharma and healthcare2 sources
3d

● mixedThe Peptide Boom That Isn’t About Your MusclesThe opportunity is pill-form peptides that could challenge big pharma’s most profitable franchisesPharma and healthcare Eli Lilly1 source
3d

Expansion● mixedOzempic & Wegovy maker Novo looks to expand India portfolio through investments in new technologiesNovo Nordisk is exploring investments in technologies to personalise diabetes and obesity treatments1 source
4d

● mixedNovo's new strategy hinges on something it can't manufacture: investor trustNovo CEO Mike Doustdar says the company can broaden its ambitions againStrategy1 source
4d